🚀 Unlock the Future of CNS Drug Discovery with Pharmidex 🧠
August 28, 2024
At
Pharmidex, we're dedicated to advancing the frontier of Central Nervous System (CNS) drug discovery. With our deep expertise in
in vitro and
in vivo models, DMPK studies, and translational science, we provide end-to-end solutions that accelerate your CNS projects from concept to clinic.
🔬 Our CNS services include:
- In vitro assays for neurotoxicity, neuroprotection, and receptor binding.
- In vivo models for a wide range of CNS disorders including
neurodegeneration, psychiatric disorders, and pain. - DMPK studies with a focus on CNS penetration, blood-brain barrier
studies, and more. - Expert consultancy to optimize your CNS drug development strategy.
Partner with us to bring innovative therapies to patients faster. Let's collaborate and make breakthroughs in CNS research together!
🌐 Explore our CNS services:
https://www.pharmidex.com/CNS
#CNS #Neuroscience #DrugDiscovery #Pharmidex #LifeSciences #Neuropharmacology #DMPK #TranslationalResearch #Biotech #Pharma
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
